Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Tarcidomgen kimleucel |
| Synonyms | |
| Therapy Description |
Limited information is currently available on Tarcidomgen kimleucel, a putative chimeric antigen receptor (CAR) T-cell therapy targeting CD19 (Jan 2024). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Tarcidomgen kimleucel | FCTX-CL19-1|FCTX CL19-1|FCTXCL19-1 | CD19 Immune Cell Therapy 72 | Limited information is currently available on Tarcidomgen kimleucel, a putative chimeric antigen receptor (CAR) T-cell therapy targeting CD19 (Jan 2024). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06593145 | Phase I | Tarcidomgen kimleucel | CAR T Cells in the Treatment of Refractory and Relapsed CD19+ B Cell Neoplasms (CARLA) | Recruiting | POL | 0 |